Online classification accuracy and ITR of each subject with two sequences for the FF and GFF spelling paradigms.

<p>Online classification accuracy and ITR of each subject with two sequences for the FF and GFF spelling paradigms.</p

Superimposed grand-averaged ERP waveforms elicited by non-target and target trials in the FF and GFF spelling paradigms.

<p>The epochs are from 100 ms before stimulus onset to 800 ms after onset.</p

Use of a Green Familiar Faces Paradigm Improves P300-Speller Brain-Computer Interface Performance - Fig 5

<p>(a) Superimposed difference waveforms of ERPs elicited by the target and non-target trials (ERP_Target—ERP_Non-target) in the FF and GFF spelling paradigms. The gray square areas indicate the time periods during which the difference waveforms of ERPs elicited by the target and non-target trials (ERP_Target—ERP_Non-target) were significantly different (p < 0.01) between the FF and GFF spelling paradigms. (b) Scalp topographies for double-difference waveforms obtained by subtracting the (ERP_Target—ERP_Non-target) waveforms for the FF spelling paradigm from those for the GFF spelling paradigm for the time periods showing significant differences (160–220 ms, 160–260 ms, 300–400 ms, and 640–680 ms).</p

The comparison of averaged amplitudes of (ERP_Target—ERP_Non-target) in four significant time periods (160–220 ms at O1, 160–260 ms at Fz, 300–400 ms at Cz, and 640–680 ms at Fz) for 17 individual subjects.

<p>The comparison of averaged amplitudes of (ERP_Target—ERP_Non-target) in four significant time periods (160–220 ms at O1, 160–260 ms at Fz, 300–400 ms at Cz, and 640–680 ms at Fz) for 17 individual subjects.</p

Two different spelling paradigms were designed and employed in this study.

<p>Translucent pictures of a familiar face (David Beckham) covered the characters in one row or column while it was intensified. (a) In the FF spelling paradigm, the characters were covered with flashing familiar faces. (b) In the GFF spelling paradigm, the characters were covered with flashing green familiar faces. The facial photographs of David Beckham are replaced by those of a subject in the figure because of the lack of a print license. The individual in the photograph has given permission for his photograph to be published.</p

EEG setup consisting of 14 electrodes.

<p>Locations were Fz, F3, F4, FC1, FC2, Cz, C3, C4, Pz, P3, P4, Oz, O1, and O2.</p

PD1 is highly expressed in diffuse large B-cell lymphoma with hepatitis B virus infection

<div><p>Objective</p><p>The purpose of this study was to determine the association between PD1 expression and the clinical prognosis of diffuse large B-cell lymphoma (DLBCL) co-occurring with hepatitis B virus (HBV) infection.</p><p>Methods</p><p>A total of 165 patients presented with newly diagnosed and untreated DLBCL at the First Hospital of Jilin University, Changchun, China, between 2011.01 and 2014.12. Complete clinical information was available for 152 of these 165 patients. We retrospectively reviewed the results of HBV serum marker assays and the clinical information of these 152 DLBCL patients from our hospital database; eventually, only 51 patients were enrolled in this study, and these 51 patients received the PD1 test item.</p><p>Results</p><p><b>①</b> The incidence of HBsAg prevalence was 13.2% (20/152) in this study; <b>②</b> The incidence of PD1 expression in the HBsAg⁺ group was 4.3-fold higher than that in the HBsAg^<b>—</b>group (40.0% <i>vs</i> 9.4%; <i>P</i> = 0.010); <b>③</b> The clinical information, including sex, age, clinical stage, IPI, molecular subtype and chemotherapy status, was analyzed between the HBsAg⁺ and HBsAg^<b>—</b>groups, but there were no significant differences between the two groups; <b>④</b> The median OS and PFS of the patients in the HBsAg⁺ group were 36.5 months and 12 months, respectively; however, the median OS and PFS of patients in the HBsAg^<b>—</b>group were not reached (<i>P</i> = 0.033) and 32 months (<i>P</i> = 0.049), respectively; and <b>⑤</b> The median OS and PFS of PD1-positive patients in the HBsAg⁺ group were the worst (24 months and 9 months, respectively), whereas the median OS and PFS of PD1-negative patients in the HBsAg^<b>—</b>group were the best (not reached and 32 months, respectively).</p><p>Conclusions</p><p>Compared with patients in the HBsAg^<b>—</b>group, the incidence of PD1 expression was significantly higher in the HBsAg⁺ group, and the median OS and PFS times were the worst in PD1-positive patients in the HBsAg⁺ group. These results indicated that the dismal prognosis of patients with HBsAg⁺ may be related to the high rate of PD1 expression. Thus, a targeted PD1 treatment strategy may improve the prognosis of HBsAg⁺ DLBCL patients.</p></div

The ratios of MPMTs in different systems.

<p>0.99% refers to the prevalence of MPMTs in 15,398 patients with malignant tumors. Group A included patients with head and neck cancer (5.65% versus 0.99%; P = 0.000), urinary tumors (4.19% versus 0.99%; P = 0.000) and gynecological tumors (1.98% versus 0.99%; P = 0.008). Group B included patients with breast cancer (1.22% versus 0.99%; P = 0.241) and digestive system tumors (1.25% versus 0.99%; P = 0.151). Group C included patients with lung cancer (0.35% versus 0.99%; P = 0.000) and leukemia/lymphoma (0.14% versus 0.99%; P = 0.000).</p

The distribution of second primary cancer in 152 MPMTs.

<p>The distribution of second primary cancer in 152 MPMTs.</p

Treatment.

<p>R: MabThera. RT: radiation therapy. P-values: the HBV-free group compared with the active infection group</p><p>Treatment.</p